Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
September 22, 2017
- Japan Oncology Market to Grow Annual 6-9% through 2021: IMS
September 21, 2017
- Opdivo Approved for Non-Squamous NSCLC in Taiwan
September 21, 2017
- Intuniv Hits Primary Endpoint in Adult ADHD: Shionogi/Shire
September 21, 2017
- Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia
September 21, 2017
- hsCRP Levels Will Be Cardiovascular Risk Predictor: Takeda’s Post-Hoc Analysis from EXAMINE Study
September 21, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in HBV Carriers Too: PIII Sub-Analysis
September 20, 2017
- Opdivo Gets Label Expansion for Melanoma in South Korea
September 20, 2017
- NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors
September 20, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Daiichi Sankyo Links Up with MD Anderson on AML Therapies
September 19, 2017
- Aptiom Gets FDA Pediatric Nod for Partial-Onset Seizures
September 19, 2017
- Xtandi Delivers Strong Data for Non-Metastatic CRPC in a Boon for Label Expansion Overseas: Astellas
September 15, 2017
- Pralia Jumps in July GP Recollection Ranking on Indication Addition: Anterio
September 15, 2017
- Chugai’s On-the-Spot ADR Info Provisioning Tools Well Received by Physicians, Spreading to Other Makers
September 15, 2017
- Shionogi to File Sakigake-Designated Flu Drug by Year-End Based on PIII Results
September 15, 2017
- NeuroDerm Shareholders OK Acquisition by Mitsubishi Tanabe
September 14, 2017
- FDA Accepts sNDA for Mirabegron Combo Therapy: Astellas
September 14, 2017
- With Canalia Debut as Catalyst, Mitsubishi Tanabe Set to Maximize 3 Diabetes Meds
September 13, 2017
- DS-8201 Data Out for Multiple HER2-Expressing Tumors: Daiichi Sankyo
September 13, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…